Chimeric immunomodulatory compounds and methods of using the same-IV
First Claim
Patent Images
1. A linear chimeric immunostimulatory compound (CIC) comprising the structure N1-S1-N2-S2-N3,wherein N1, N2, and N3 are independently selected nucleic acid moieties, at least one of N1, N2, and N3 has the sequence 5′
- -TCGY-3′
, where Y is selected from the group consisting of XCGX, XTCG, XXCG, and CGXX, where each X is an independently selected nucleotide;
wherein S1 is a non-nucleic acid spacer moiety covalently bound to N1 and N2;
S2 is a non-nucleic acid spacer moiety covalently bound to N2 and N3;
S1 and S2 are the same or different;
each of S 1 and S2 comprises hexaethylene glycol (HEG), triethylene glycol (TEG), propyl, butyl, or hexyl; and
wherein said CIC has at least one immunostimulatory activity selected from the group consisting of (i) the ability to stimulate interferon-gamma (IFN-γ
) production by human peripheral blood mononuclear cells or (ii) the ability to stimulate interferon-alpha (IFN-α
) production by human peripheral blood mononuclear cells.
3 Assignments
0 Petitions
Accused Products
Abstract
The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds.
-
Citations
18 Claims
-
1. A linear chimeric immunostimulatory compound (CIC) comprising the structure N1-S1-N2-S2-N3,
wherein N1, N2, and N3 are independently selected nucleic acid moieties, at least one of N1, N2, and N3 has the sequence 5′ - -TCGY-3′
, where Y is selected from the group consisting of XCGX, XTCG, XXCG, and CGXX, where each X is an independently selected nucleotide;wherein S1 is a non-nucleic acid spacer moiety covalently bound to N1 and N2;
S2 is a non-nucleic acid spacer moiety covalently bound to N2 and N3;
S1 and S2 are the same or different;
each of S 1 and S2 comprises hexaethylene glycol (HEG), triethylene glycol (TEG), propyl, butyl, or hexyl; andwherein said CIC has at least one immunostimulatory activity selected from the group consisting of (i) the ability to stimulate interferon-gamma (IFN-γ
) production by human peripheral blood mononuclear cells or (ii) the ability to stimulate interferon-alpha (IFN-α
) production by human peripheral blood mononuclear cells. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18)
- -TCGY-3′
-
9. A linear chimeric immunostimulatory compound (CIC) comprising the structure N1-S1-N2-S2-N3, wherein N1, N2, and N3 are independently selected nucleic acid moieties and wherein at least one nucleic acid moiety comprises the sequence 5′
- -AACGTTC-3′
, 5′
-AACGTT-3′
, 5′
-ATCGT-3′
, 5′
-ATCGAT-3′
, 5′
-ACCGGT-3′
, 5′
-AGCGTT-3′
, 5′
-ATCGTT-3′
, 5′
-AACGAT-3′
, 5′
-AACGCT-3′
, 5′
-AACGTG-3′
, 5′
-AACGTA-3′
, or 5′
-AACGTC-3′
, wherein S1 is a non-nucleic acid spacer moiety covalently bound to N1 and N2;
S2 is a non-nucleic acid spacer moiety covalently bound to N2 and N3;
S1 and S2 are the same or different;
each of S1 and S2 comprises hexaethylene glycol (HEG), triethylene glycol (TEG), propyl, butyl, or hexyl; andwherein said CIC has at least one immunostimulatory activity selected from the group consisting of (i) the ability to stimulate interferon-gamma (IFN-γ
) production by human peripheral blood mononuclear cells or (ii) the ability to stimulate interferon-alpha (IFN-α
) production by human peripheral blood mononuclear cells. - View Dependent Claims (10)
- -AACGTTC-3′
Specification